Skip to main content
. 2019 May 13;76(8):906–914. doi: 10.1001/jamaneurol.2019.1120

Figure 1. Relative Risk (RR) for Intracranial Hemorrhage (Aspirin vs Placebo or No Aspirin).

Figure 1.

The sizes of the data markers indicate the weight of each trial. AAA indicates the Aspirin for Asymptomatic Atherosclerosis trial; APLASA, the Antiphospholipid Antibody Acetylsalicylic Acid study; ARRIVE, the Aspirin to Reduce Risk of Initial Vascular Events study; ASCEND, A Study of Cardiovascular Events in Diabetes; ASPREE, the Aspirin in Reducing Events in the Elderly trial; ECLAP, the European Collaboration on Low-Dose Aspirin in Polycythemia Vera; HOT, the Hypertension Optimal Treatment Study; JPAD, the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial; JPPP, the Japanese Primary Prevention Project; POPADAD, the Prevention of Progression of Arterial Disease and Diabetes trial; PPP, the Primary Prevention Project; and WHS, the Women’s Health Study.